We are live on ! Find out more
FLSM

Frazier Life Sciences Management Portfolio holdings

AUM $3.89B
1-Year Est. Return 201.1%
This Fund
S&P 500
This Quarter Est. Return
-3.63%
1 Year Est. Return
+201.1%
3 Year Est. Return
+879.31%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$2.14B
AUM Growth
-$232M
Cap. Flow
-$62.6M
Cap. Flow %
-2.93%
Top 10 Hldgs %
61.97%
Holding
57
New
7
Increased
13
Reduced
4
Closed
8

Top Buys

1
ERAS icon
Erasca
ERAS
+$35M
2
IRON icon
Disc Medicine
IRON
+$33M
3
ANAB icon
AnaptysBio
ANAB
+$29.5M
4
SVRA icon
Savara
SVRA
+$18.5M
5
RARE icon
Ultragenyx Pharmaceutical
RARE
+$18.1M

Top Sells

1
ALPN
Alpine Immune Sciences Inc
ALPN
+$124M
2
APLS
Apellis Pharmaceuticals
APLS
+$52M
3
JBIO
Jade Biosciences
JBIO
+$35.6M
4
GPCR icon
Structure Therapeutics
GPCR
+$27M
5
DCPH
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
+$22.9M

Sector Composition

1 Healthcare 99.8%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
JBIO
51
Jade Biosciences
JBIO
$1.25B
– –
-34,425
Closed -$35.6M
BLUE
52
DELISTED
bluebird bio
BLUE
– –
-85,495
Closed -$2.19M
GPCR icon
53
Structure Therapeutics
GPCR
$3.27B
– –
-629,194
Closed -$27M
NTLA icon
54
Intellia Therapeutics
NTLA
$1.66B
– –
-203,684
Closed -$5.6M
GRTS
55
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
– –
-1,030,878
Closed -$2.65M
DCPH
56
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
– –
-1,455,837
Closed -$22.9M
ALPN
57
DELISTED
Alpine Immune Sciences Inc
ALPN
– –
-3,131,008
Closed -$124M
1 2
3

Similar funds

GAMH
Greenwoods Asset Management (HK) Hong Kong $3.88B AUM 23.82% 1-Year Est. Return
MSI
Mitsui Sumitomo Insurance Tokyo, Japan $3.9B AUM
CCM
Channing Capital Management Chicago, Illinois $3.91B AUM 34.32% 1-Year Est. Return
TFM
Trian Fund Management New York $3.86B AUM 26.59% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
MIM
Meridiem Investment Management London, United Kingdom $3.92B AUM 1.64% 1-Year Est. Return
AA
Alesco Advisors Pittsford, New York $3.92B AUM 15.21% 1-Year Est. Return
DACG
Donor Advised Charitable Giving San Francisco, California $3.92B AUM 59.92% 1-Year Est. Return

Frazier Life Sciences Management's Q2 2024 Portfolio in Review

As of Q2 2024, Frazier Life Sciences Management held 57 positions worth $2.14B, down 9.8% from $2.37B the previous quarter. Its ten largest holdings account for 62% of the portfolio.

Frazier Life Sciences Management's Q2 2024 filing shows 7 new, 13 increased, 4 reduced and 8 closed positions. Its largest new stake was Erasca: 16,216,216 shares worth $38.3M. The largest sale was Alpine Immune Sciences Inc, an estimated $124M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier.

  • Frazier Life Sciences Management's largest Q2 2024 buy was Erasca: 16,216,216 shares worth $38.3M.
  • Frazier Life Sciences Management added most to Disc Medicine in Q2 2024, an estimated $33M increase.
  • Frazier Life Sciences Management's biggest Q2 2024 reduction was Merus, cutting an estimated $18.1M.
  • Frazier Life Sciences Management fully exited Alpine Immune Sciences Inc in Q2 2024, selling an estimated $124M.
  • Frazier Life Sciences Management's ten largest holdings make up 62% of its $2.14B portfolio in Q2 2024.
  • Frazier Life Sciences Management opened 7 new positions and closed 8 in Q2 2024.
  • Frazier Life Sciences Management's portfolio value fell 9.8% quarter-over-quarter to $2.14B.

Based on Frazier Life Sciences Management's 13F filing for Q2 2024, filed 15 Aug 2024.